|
시장보고서
상품코드
1937771
퓨전 생검 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)Global Fusion Biopsy Market Size, Share, Trends & Growth Analysis Report 2026-2034 |
||||||
퓨전 생검 시장 규모는 2025년 14억 5,000만 달러에서 2026년부터 2034년까지 CAGR 8.3%로 성장하여 2034년에는 29억 8,000만 달러에 달할 것으로 예측됩니다.
영상기술의 발전과 전립선암 발병률 증가를 배경으로 퓨전 생검 시장은 괄목할만한 성장세를 보이고 있습니다. 퓨전 생검은 기존 초음파 영상과 자기공명영상(MRI)을 융합하여 전립선암 진단의 정확도를 높입니다. 이 혁신적인 방법은 의심스러운 병변의 표적 샘플링을 가능하게 하여 임상적으로 중요한 암의 검출률을 높이고 불필요한 생검을 최소화할 수 있습니다. 전립선암에 대한 인식이 높아지고 검진 지침이 발전함에 따라 퓨전 생검 시술에 대한 수요가 증가할 것으로 예상되며, 이 시장은 견조한 성장이 예상됩니다.
또한, 맞춤형 의료에 대한 관심이 높아지면서 퓨전 생검의 트렌드에 영향을 미치고 있습니다. 종양의 특성에 대한 보다 정밀한 정보를 제공함으로써 의료진은 환자 개개인에 맞는 치료 계획을 수립할 수 있습니다. 이러한 표적 치료로의 전환은 종양의 특정 생물학적 특성을 이해하는 것이 치료 결과에 큰 영향을 미치는 종양학 분야에서 특히 중요합니다. 의료 시스템이 점점 더 정밀 의료 접근 방식을 채택함에 따라 퓨전 생검 시장은 환자 치료를 개선하고 자원 활용을 최적화하기 위한 첨단 진단 도구의 통합을 통해 혜택을 받을 가능성이 높습니다.
또한, 최소침습수술의 보급이 퓨전 생검 기술의 채택을 촉진하고 있습니다. 환자들은 불편함과 회복 기간을 줄일 수 있는 방법을 찾는 경향이 강해지고 있으며, 퓨전 생검은 기존의 생검법을 대체할 수 있는 매력적인 대안으로 주목받고 있습니다. 의료 종사자를 위한 사용하기 쉬운 장비와 교육 프로그램 개발도 이 기술의 보급을 더욱 촉진하고 있습니다. 퓨전 생검 시장이 계속 진화하는 가운데, 지속적인 연구개발은 그 적용 범위 확대와 진단 정확도 향상에 중요한 역할을 할 것이며, 궁극적으로 전립선암과 싸우는 환자들의 치료 성과 향상에 기여할 것입니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 퓨전 생검 시장 : 기술 타겟별
제5장 세계의 퓨전 생검 시장 : 제품별
제6장 세계의 퓨전 생검 시장 : 용도별
제7장 세계의 퓨전 생검 시장 : 기술별
제8장 세계의 퓨전 생검 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
KSM 26.03.12The Fusion Biopsy Market size is expected to reach USD 2.98 Billion in 2034 from USD 1.45 Billion (2025) growing at a CAGR of 8.3% during 2026-2034.
The fusion biopsy market is experiencing significant growth, driven by advancements in imaging technologies and the increasing prevalence of prostate cancer. Fusion biopsy combines traditional ultrasound imaging with magnetic resonance imaging (MRI) to enhance the accuracy of prostate cancer diagnosis. This innovative approach allows for targeted sampling of suspicious lesions, improving the detection rate of clinically significant cancers while minimizing unnecessary biopsies. As awareness of prostate cancer rises and screening guidelines evolve, the demand for fusion biopsy procedures is expected to increase, positioning this market for robust expansion.
Moreover, the growing emphasis on personalized medicine is influencing the fusion biopsy landscape. By providing more precise information about tumor characteristics, fusion biopsy enables healthcare providers to tailor treatment plans to individual patients. This shift towards targeted therapies is particularly relevant in oncology, where understanding the specific biology of a tumor can significantly impact treatment outcomes. As healthcare systems increasingly adopt precision medicine approaches, the fusion biopsy market is likely to benefit from the integration of advanced diagnostic tools that enhance patient care and optimize resource utilization.
Additionally, the rise of minimally invasive procedures is driving the adoption of fusion biopsy techniques. Patients are increasingly seeking options that reduce discomfort and recovery time, making fusion biopsy an attractive alternative to traditional biopsy methods. The development of user-friendly devices and training programs for healthcare professionals is further facilitating the adoption of this technology. As the fusion biopsy market continues to evolve, ongoing research and innovation will play a crucial role in expanding its applications and improving diagnostic accuracy, ultimately contributing to better patient outcomes in the fight against prostate cancer.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Tech Target
- DNA
- RNA
- Protein
By Product
- Multi-gene Panels
- Single-gene Tests
- Companion Diagnostics
- Research Use Only (RUO) Kits
By Application
- Oncology
- Neurology
- Infectious Diseases
- Cardiovascular Diseases
By Technology
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Digital PCR
- NanoString Technologies
COMPANIES PROFILED
- Hologic, Inc, Exact Sciences Corporation, Myriad Genetics, Inc, BioRad Laboratories, Inc, Invivoscribe, Leica Biosystems, Affymetrix, Inc, Qiagen NV, BD Becton, Dickinson and Company, Agilent Technologies, Inc, Genomic Health, Sysmex Corporation, Beckman Coulter, Inc, Thermo Fisher Scientific Inc, Illumina, Inc
We can customise the report as per your requriements
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL FUSION BIOPSY MARKET: BY TECH TARGET 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Tech Target
- 4.2. DNA Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. RNA Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.4. Protein Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL FUSION BIOPSY MARKET: BY PRODUCT 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Product
- 5.2. Multi-gene Panels Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. Single-gene Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.4. Companion Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.5. Research Use Only (RUO) Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL FUSION BIOPSY MARKET: BY APPLICATION 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast Application
- 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.5. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL FUSION BIOPSY MARKET: BY TECHNOLOGY 2022-2034 (USD MN)
- 7.1. Market Analysis, Insights and Forecast Technology
- 7.2. Next-Generation Sequencing (NGS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.3. Polymerase Chain Reaction (PCR) Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.4. Digital PCR Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.5. NanoString Technologies Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL FUSION BIOPSY MARKET: BY REGION 2022-2034(USD MN)
- 8.1. Regional Outlook
- 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.2.1 By Tech Target
- 8.2.2 By Product
- 8.2.3 By Application
- 8.2.4 By Technology
- 8.2.5 United States
- 8.2.6 Canada
- 8.2.7 Mexico
- 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.3.1 By Tech Target
- 8.3.2 By Product
- 8.3.3 By Application
- 8.3.4 By Technology
- 8.3.5 United Kingdom
- 8.3.6 France
- 8.3.7 Germany
- 8.3.8 Italy
- 8.3.9 Russia
- 8.3.10 Rest Of Europe
- 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.4.1 By Tech Target
- 8.4.2 By Product
- 8.4.3 By Application
- 8.4.4 By Technology
- 8.4.5 India
- 8.4.6 Japan
- 8.4.7 South Korea
- 8.4.8 Australia
- 8.4.9 South East Asia
- 8.4.10 Rest Of Asia Pacific
- 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.5.1 By Tech Target
- 8.5.2 By Product
- 8.5.3 By Application
- 8.5.4 By Technology
- 8.5.5 Brazil
- 8.5.6 Argentina
- 8.5.7 Peru
- 8.5.8 Chile
- 8.5.9 South East Asia
- 8.5.10 Rest of Latin America
- 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.6.1 By Tech Target
- 8.6.2 By Product
- 8.6.3 By Application
- 8.6.4 By Technology
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
- 8.6.7 Israel
- 8.6.8 South Africa
- 8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
- 9.1. Recent Developments
- 9.2. Company Categorization
- 9.3. Supply Chain & Channel Partners (based on availability)
- 9.4. Market Share & Positioning Analysis (based on availability)
- 9.5. Vendor Landscape (based on availability)
- 9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL FUSION BIOPSY INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Company Profiles
- 10.2.1 HologicInc
- 10.2.2 Exact Sciences Corporation
- 10.2.3 Myriad GeneticsInc
- 10.2.4 BioRad LaboratoriesInc
- 10.2.5 Invivoscribe
- 10.2.6 Leica Biosystems
- 10.2.7 AffymetrixInc
- 10.2.8 Qiagen N.V
- 10.2.9 BD (Becton, Dickinson And Company)
- 10.2.10 Agilent TechnologiesInc
- 10.2.11 Genomic Health
- 10.2.12 Sysmex Corporation
- 10.2.13 Beckman CoulterInc
- 10.2.14 Thermo Fisher Scientific Inc
- 10.2.15 IlluminaInc
